Abstract
A systematic review relating to NMIBC and intravesical chemotherapy was conducted. This was to identify oncoloigcal outcomes from intravesical chemotherapy. The search strategy aimed to identify all references related to NMIBC AND Intravesical Chemotherapy. This chapter deals with systematic review results.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ajili F, Darouiche A, Chebil M, Boubaker S. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer. Ultrastruct Pathol. 2013a;37(4):278–83.
Ajili F, Darouiche A, Chebil M, Boubaker S. The impact of age and clinical factors in non-muscle-invasive bladder cancer treated with Bacillus Calmette Guerin therapy. Ultrastruct Pathol. 2013b;37(3):191–5.
Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, Witte B, Newling D, Beckers GMA, van Moorselaar RJA. Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol. 2018a;73(2):226–232.
Bosschieter J, van Moorselaar RJA, Vis AN, van Ginkel T, Lissenberg-Witte BI, Beckers GMA, Nieuwenhuijzen JA. The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. BJU Int. 2018b.
Cookson MS, Chang SS, Lihou C, Li T, Harper SQ, Lang Z, Tutrone RF. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol. 2014;6(5):181–91.
De Nunzio C, Carbone A, Albisinni S, Alpi G, Cantiani A, Liberti M, Tubaro A, Iori F. Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. World J Urol. 2011;29(4):517–21.
Decaestecker K, Lumen N, Ringoir A, Oosterlinck W. Ablative intravesical chemotherapy for small recurrent non-muscle-invasive bladder cancer: a prospective study. Urol Int. 2016;96(1):14–9.
Farah NB, Ghanem R, Amr M. Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC). BMC Urol. 2014;14:11. https://doi.org/10.1186/1471-2490-14-11.
Gudjónsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl PO, Månsson W, Liedberg F. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol. 2009;55(4):773–80.
Han KS, You D, Jeong IG, Kwon T, Hong B, Hong JH, Ahn H, Ahn TY, Kim CS. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate. J Korean Med Sci. 2015;30(3):252–8.
Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol. 2012;30(18):2273–9.
O’Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int. 2013;112(8):1096–104.
Ofude M, Kitagawa Y, Yaegashi H, Izumi K, Ueno S, Kadono Y, Konaka H, Mizokami A, Namiki M. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer. J Cancer Res Clin Oncol. 2015;141(1):161–8.
Palou-Redorta J, Rouprêt M, Gallagher JR, Heap K, Corbell C, Schwartz B. The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries. World J Urol. 2014;32(2):525–30.
Racioppi M, Volpe A, Cappa E, D’Agostino D, Pinto F, D’Addessi A, Sacco E, Bassi P. Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach. Urol Int. 2010;85(3):266–9.
Serretta V, Morgia G, Altieri V, Di Lallo A, Ruggiero G, Salzano L, Battaglia M, Falsaperla M, Zito A, Sblendorio D, Melloni D, Allegro R, Members of Gruppo Studi Tumori Urologici (GSTU) Foundation. A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. BJU Int. 2010;106(2):212–7.
Serretta V, Sommatino F, Gesolfo CS, Franco V, Cicero G, Allegro R. Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy. Urol Ann. 2015;7(1):21–5.
Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Piñeiro L, Rabadan M, Ojea A, Rodriguez-Molina J, Beardo P, Muntañola P, Gomez M, Montesinos M, Martinez Piñeiro JA, Members of Club Urológico Español de Tratamiento Oncológico. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol. 2015;67(3):508–16.
Spencer BA, McBride RB, Hershman DL, Buono D, Herr HW, Benson MC, Gupta-Mohile S, Neugut AI. Adjuvant intravesical bacillus calmette-guérin therapy and survival among elderly patients with non-muscle-invasive bladder cancer. J Oncol Pract. 2013;9(2):92–8.
Stroman L, Tschobotko B, Abboudi H, Ellis D, Mensah E, Kaneshayogan H, Mazaris E. Improving compliance with a single post-operative dose of intravesical chemotherapy after transurethral resection of bladder tumour. Nephrourol Mon. 2016;8(1):e29967.
Svatek RS, Zhao XR, Morales EE, Jha MK, Tseng TY, Hugen CM, Hurez V, Hernandez J, Curiel TJ. Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. Clin Cancer Res. 2015;21(2):303–11.
Weiss BE, Pietzak EJ, Wein AJ, Malkowicz SB, Guzzo TJ. Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer. Can J Urol. 2015;22(4):7876–81.
Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, Böhle A. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). JU Int. 2013;112(6):742–50.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Goonewardene, S.S., Persad, R., Motiwala, H., Albala, D. (2020). A Systematic Review of NMIBC and Intravesical Chemotherapy—Results. In: Management of Non-Muscle Invasive Bladder Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-28646-0_35
Download citation
DOI: https://doi.org/10.1007/978-3-030-28646-0_35
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-28645-3
Online ISBN: 978-3-030-28646-0
eBook Packages: MedicineMedicine (R0)